期刊
CURRENT HEMATOLOGIC MALIGNANCY REPORTS
卷 13, 期 2, 页码 91-99出版社
CURRENT MEDICINE GROUP
DOI: 10.1007/s11899-018-0440-3
关键词
Acute lymphoblastic leukemia; Older adults; Elderly; Inotuzumab ozogamicin; Blinatumomab; Philadelphia chromosome
资金
- MD Anderson Cancer Center Support Grant [CA016672]
- NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER
Purpose of Review Older adults with acute lymphoblastic leukemia (ALL) have worse survival compared to their younger counterparts. Here, we review the reasons for the poorer outcomes of older patients with ALL and also summarize the current and future therapeutic approaches to ALL in the elderly population. Recent Findings The poor outcomes of older adults with ALL are driven largely by lack of tolerance to standard-dose chemotherapy, which leads to unacceptably high rates of myelosuppression-related deaths. Recent studies have shown promising results with the use of low-intensity or chemotherapy-free regimens in older patients with ALL, which are able to retain efficacy without excess toxicity. Summary Novel antibody constructs such as inotuzumab ozogamicin and blinatumomab as well as potent later-generation tyrosine kinase inhibitors such as ponatinib hold significant promise in the management of ALL in the older adult. Innovative combination strategies may further improve the outcomes of these patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据